Drug Development Team

We have an integrated team of experienced executives who are leading the advancement of our breakthrough discoveries into clinical development. The members of this team have had significant success in drug development and possess expertise extending from preclinical and clinical development through market approval.

Lexicon Drug Development Team
Alan S. Nies, M.D., Company Director and Chairman of Lexicon's Medical Advisory Board

Forty years of clinical and pharmacological experience.
Former Senior Vice President of Clinical Sciences at Merck & Co., Inc., responsible for all clinical programs worldwide.

Philip M. Brown, M.D., J.D., Vice President of Clinical Development

Fourteen years of experience managing medical affairs, drug safety and clinical programs in multiple therapeutic areas.
Served as a clinical investigator on more than 200 clinical trials.

William E. Heydorn, Ph.D., Vice President of Preclinical Development

Twenty years of experience in preclinical and clinical drug development, pharmaceutical operations, project management and regulatory affairs.
Experience with more than 20 IND and NDA filings.

Alan G.E. Wilson, Ph.D., Vice President of Drug Metabolism and Pharmacokinetics

Twenty-five years of experience in drug safety and drug metabolism within the pharmaceutical and life science industries.
Former Global Head of Preclinical Profiling at Pharmacia Corporation.